Pitch deck
Cyclica
Cyclica's drug discovery pitch deck accelerating pharmaceutical research with computational biology.
- Industry
- Healthcare
- Stage
- Series B
- Founded
- 2013
- Deck year
- 2020
The deck
About the company
Cyclica Inc. applies AI to drug discovery through polypharmacology, headquartered in Toronto. Focuses on understanding how drugs interact with multiple protein targets. It raised $21M over 7 funding rounds, with Series B at $17M before Recursion acquired them for $40M.
The breakdown
What Is the Cyclica Pitch Deck?
The Cyclica pitch deck presented:
AI-powered polypharmacology analysis
Drug-protein interaction mapping
Side effect prediction
Drug repositioning opportunities
Comprehensive target identification
Understanding how drugs really work.
Why the Cyclica Pitch Deck Works The deck succeeds because it:
Shows deep scientific credibility
Demonstrates clear pharma partnership model
Presents differentiated technology approach
Key Capabilities Highlighted
Polypharmacology analysis
Off-target interaction prediction
Side effect forecasting
Drug repositioning identification
Product Vision: Understand How Drugs Really Work Cyclica positioned as revealing the complete picture of drug interactions, not just intended targets, but all protein interactions.
Market Opportunity Pharmaceutical companies needing better drug candidate selection. Massive R&D waste from failed candidates.
Business Model Research partnerships and platform licensing with pharmaceutical companies. Revenue tied to discovery milestones.
Scientific Depth as Moat Proprietary technology for comprehensive protein interaction analysis creates differentiation in technical market.
Founder insight: In biotech, scientific rigor matters. Demonstrate deep expertise before seeking scale.
This Pitch Deck is taken from Best Pitch Deck.
Biotech investors at SheetVenture.
Frequently asked questions
1. What exactly is Venture Sheet?
Venture Sheet is a powerful, all-in-one Google Sheet that gives you instant access to 1,000+ active investors — updated daily.
2. What drug discovery challenge did Cyclica identify for pharmaceutical companies?
Cyclica identified that traditional drug discovery was slow, expensive, and failed to predict adverse effects or off-target interactions.
3. How does Cyclica's AI platform accelerate identification of safer medicines?
Cyclica uses proteome-wide screening and AI to predict how drug candidates interact with all human proteins, reducing failures.
More decks in this space
Find the investors who fund decks like this
A deck only works in front of investors who are actually active in your stage and sector. That is the part SheetVenture answers.